Google-backed Calico doubles down on anti-aging R&D pact with AbbVie as partners ante up $1B, start to detail drug targets
Seven years after striking up a major R&D alliance, AbbVie and Google-backed anti-aging specialist Calico are doubling down on their work with a joint, $1 billion commitment to continuing their work together. And they’re also beginning to offer some details on where this project is taking them in the clinic.
According to their statement, each of the two players is putting up $500 million more to keep the labs humming.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.